Advanced search
Publication Cover
Expert Opinion on Therapeutic Patents Volume 13, 2003 - Issue 6
Submit an article Journal homepage
39
Views
2
CrossRef citations to date
0
Altmetric
Review

Progress on novel immunomodulatory agents for HIV-1 infection and other infectious diseases

K Noel Masihi Robert Koch Institute, Nordufer 20, D – 13353, Berlin, Germany. [email protected]
Pages 867-882 | Published online: 02 Mar 2005

Bibliography

  • KSIAZEK TG, ERDMAN D, GOLDSMITH C et al.: The SARS: a novel coronavirus associated with severe acute respiratory syndrome. N Engl. I Med. (2003) NEJM0a030781.
  • AMYES SGB: The rise in bacterial resistance is partly because there have been no new classes of antibiotics since the 1960s. Br. Med. J. (2000) 320:199–200.
  • TAYLOR PW, STAPLETON PD, PAUL LJ: New ways to treat bacterial infections. Drug Discov. Today (2002) 7:1086–1091.
  • MCGUIRK P, MILLS KHG: Pathogen-specific regulatory T cells provoke a shift in the Thl/Th2 paradigm in immunity to infectious diseases. Trends in Immunology (2002) 23:450–455.
  • MASIHI KN: Fighting infection using immunomodulatory agents. Expert. Opin. Biol. Ther. (2001) 1:641–653.
  • MASIHI KN: Immunomodulatory agents for prophylaxis and therapy of infections. Int. .1. Antimicrobial Agents (2000) 14:181–191.
  • HENGEL H, MASIHI KN: Combinatorial immunotherapies for infectious diseases. Int. Immunopharmacol (2003) 3:1–9.
  • HORUK R: Chemokine receptors. Cytokine & Growth Factor Reviews (2001) 12:313–335.
  • •Presents an overview of chemokine receptors.
  • HEENEY JL: The critical role of CD4+ T cell help in immunity to HIV. Vaccine (2002) 20: 1961-1963.
  • AQUARO S, CALIO R, BALZARINI J, BELLOCCHI MC, GARACI E, PERNO CF: Macrophages and HIV infection: therapeutical approaches toward this strategic virus reservoir. Antiviral Res. (2002) 55:209–225.
  • CHINEN J, SHEARER WT: Molecular virology and immunology of HIV infection. J. Allergy Clin. Irnmunol. (2002) 110:189–198.
  • BERGER EA, MURPHY PM, FARBER JM: Chemokine receptors as HIV-1 coreceptors: roles in viral entry, tropism, and disease. Ann. Rev Immunol (1999) 17:657–700.
  • NANSEN A, CHRISTENSEN JP, ANDREASEN SO, BARTHOLDY C, CHRISTENSEN JE, THOMSEN AR: The role of CC chemokine receptor 5 in antiviral immunity. Blood (2002) 99:1237–1245.
  • DRAGIC T: An overview of the determinants of CCR5 and CXCR4 co-receptor function. Gen. Virol (2001) 82:1807–1814.
  • DENG H, LIU R, ELLMEIER W, CHOE S et al.: Identification of a major co-receptor for primary isolates of HIV-1. Nature (1996) 381:661–666.
  • LEHNER T: The role of CCR5 chemokine ligands and antibodies to CCR5 coreceptors in preventing HIV infection. Trends Immunol (2002) 23:347–351.
  • •Sunurtarises the role of CCR5 in HIV.
  • KAZMIERSKI WM, BOONE L, LAWRENCE W, WATSON C, KENAKIN T: CCR5 chemokine receptors: gatekeepers of HIV-1 infection. Curr: Drug Targets. Infect. Disord. (2002) 2:265–278.
  • BLANPAIN C, LIBERT F, VASSART G, PARMENTIER M: CCR5 and HIV infection. Receptors Channels (2002) 8:19–31.
  • ALKHATIB G, COMBADIERE C, BRODER CC et al: CC CKR5: a RANTES, MIP- la, MIP-113 receptor as a fusion cofactor for macrophage-tropic HIV-1. Science (1996) 272: 1955-1958.
  • WETZEL MA, STEELE AD, HENDERSON EE, ROGERS TJ: The effect of X4 and R5 HIV-1 on C, CC, and CXC chemokines during the early stages of infection in human PBM Cs. Virology (2002) 292:6–15.
  • FERNANDEZ EJ, LOLIS E: Structure, function, and inhibition of chemokines. Ann. Rev. Pharmacol Toxicol (2002) 42:469–499.
  • PANI A, LOI AG, MURA M, MARCEDDU T, LA COLLA P, MARONGIUME: Targeting HIV: old and new players. Cum Drug Targets Infect. Disoirl (2002) 2:17–32.
  • LUSSO P: HIV and chemokines: implications for therapy and vaccine. Vaccine (2002) 20:1964–1967.
  • SCOZZAFAVA A, MASTROLORENZO A, SUPURAN CT: Non-peptidic chemokine receptors antagonists as emerging anti-HIV agents. I Enzyme Inhib. Med. Chem (2002) 17:69–76.
  • VERANI A, LUSSO P: Chemokines as natural HIV antagonists. Curr: Ma Med. (2002) 2:691–702.
  • PROUDFOOT AEI, POWER CA, ROMMEL C, WELLS TNC: Strategies for chemokine antagonists as therapeutics. Semin. Immunol (2003) 15(1):57–65.
  • ••This paper discusses leading strategies thatmight be useful for developing chemokine-based drugs.
  • REGOES RR, BONHOEFFER SEBA: HIV coreceptor usage and drug treatment. .1. Theor: Biol. (2002) 217:443–457.
  • ONUFFER JJ, HORUK R: Chemokines, chemokine receptors and small-molecule antagonists: recent developments. Trends Pharmacol Sci. (2002) 23:459–467.
  • ALFANO M, SCHMIDTMAYEROVA H, AMELLA CA, PUSHKARSKY T, BUKRINSKY M: The B-oligomer of pertussis toxin deactivates CC chemokine receptor 5 and blocks entry of M-tropic HIV-1 strains. I Exp. Med. (1999) 190:597–605.
  • RICHARDSON RM, TOKUNAGA K, MARJORAM R, SATA T, SNYDERMAN R: Interleukin-8-mediated heterologous receptor internalization provides resistance to HIV-1 infectivity: role of signal strength and receptor desensitization. j Biol. Chem. (2003) 278(18):15867–15873.
  • LANE BR, STRIETER RM, COFFEY MJ, MARKOVITZ DM: Human immunodeficiency virus Type 1 (HIV-1)-induced GRO-a production stimulates HIV-1 replication in macrophages and T lymphocytes. Virol. (2001) 75:5812–5822.
  • LANE BR, LORE K, BOCK PJ et al.: Interleukin-8 stimulates human immunodeficiency virus Type 1 replication and is a potential new target for antiretroviral therapy.Virol. (2001)75:8195–8202.
  • RUFF MR, MELENDEZ- GUERRERO LM, YANG Qe et al.: Peptide T inhibits HIV-1 infection mediated by the chemokine receptor-5 (CCR5). Antiviral Res. (2001) 52:63–75.
  • TAMAMURA H, HIRAMATSU K, MIYAMOTO K et al.: Synthesis and evaluation of pseudopeptide analogues of a specific CXCR4 inhibitor, T140: the insertion of an (E)-alkene dipeptide isostere into the [I3] IY-turn moiety. Bioorg. Med. Chem. Lett. (2002) 12:923–928.
  • STRIZKI JM, XU S, WAGNER NE et al.: SCH-C (SCH 351125), an orally bioavailable, small molecule antagonist of the chemokine receptor CCR5, is a potent inhibitor of HIV-1 infection M vitro and in vivo. PNAS (2001) 98:12718–12723.
  • TRKOLA A, KUHMANN SE, STRIZKI JM et al.: HIV-1 escape from a small molecule, CCR5-specific entry inhibitor does not involve CXCR4 use. PNAS (2002) 99:395–400.
  • VICENZI E, ALFANO M, GHEZZI S et al.: Divergent regulation of HIV-1 replication in PBMC of infected individuals by CC chemokines: suppression by RANTES, MIP-la, and MCP-3, and enhancement by MCP-1.j Leukoc. Biol. (2000) 68:405–412.
  • LUSSO P: HIV and chemokines: implications for therapy and vaccine. Vaccine (2002) 20:1964–1967.
  • POLO S, NARDESE V, DE SANTIS C et al.: Enhancement of the HIV-1 inhibitory activity of RANTES by modification of the N-terminal region: dissociation from CCR5 activation. Eur: Immunol. (2000) 30:3190–3198.
  • RUSCONI S, LA SETA C, CITTERIO P et al.: Combination of CCR5 and CXCR4 inhibitors in therapy of human immunodeficiency virus Type 1 infection: in vitro studies of mixed virus infections. Virol. (2000) 74:9328–9332.
  • MENTEN P, WUYTS A, VAN DAMME J: Macrophage inflammatory protein-1. Cytokine Growth Factor Rev (2002) 13:455–481.
  • •Reviews current understanding on the role of MIP-1.
  • PINTO LA, WILLIAMS MS, DOLAN MJ, HENKART PA, SHEARER GM: P-chemokines inhibit activation-induced death of lymphocytes from HIV-infected individuals. Ear: j Immunol. (2000) 30:2048–2055.
  • LEHRER RI, GANZ T: Defensins of vertebrate animals. Curl: Opin. Immunol. (2002) 14:96–102.
  • RAJ PA, DENTINO AR: Current status of defensins and their role in innate and adaptive immunity. FEMS Microbiology Letters (2002) 206:9–18.
  • ZHANG L, YU W, HE T et al.: Contribution of human a-defensin 1,2, and 3 to the anti-HIV-1 activity of CD8 antiviral factor. Science (2002) 298:995–1000.
  • ••This paper describes the role of defensins in HIV.
  • NAKASHIMA H, YAMAMOTO N, MASUDA M, FUJII N: Defensins inhibit HIV replication M vitro. AIDS (1993) 7(8):1129.
  • MONELL CR, STRAND M: Structural and functional similarities between synthetic HIV gp41 peptides and defensins. Clin. Immunol. Immunopathol. (1994) 71:315–324.
  • COLE AM, HONG T, BOO LM et al.: Retrocyclin: a primate peptide that protects cells from infection by T- and M-tropic strains of HIV-1. Proc. Nati Acad. Sci. USA (2002) 99:1813–1818.
  • BIRAGYN A, BELYAKOV IM, CHOW YH, DIMITROV DS, BERZOFSKY JA, KWAK LW: DNA vaccines encoding human immunodeficiency virus-1 glycoprotein 120 fusions with proinflammatory chemoattractants induce systemic and mucosal immune responses. Blood (2002) 100:1153–1159.
  • COLE AM, LIAO HI, GANZ T, YANG OO: Antibacterial activity of peptides derived from envelope glycoproteins of HIV-1. FEBS Lett. [In Press]
  • ARTHOS J, CICALA C, STEENBEKE TD et al.: Biochemical and biological characterization of a dodecameric CD4-Ig fusion protein: implications for therapeutic and vaccine strategies. Biol. Chem. (2002) 277:11456–11464.
  • JACOBSON JM, LOWY I, FLETCHER CV et al.: Single-dose safety, pharmacology, and antiviral activity of the human immunodeficiency virus (HIV) Type 1 entry inhibitor PRO 542 in HIV-infected adults. Infect. Dis. (2000) 182:326–329.
  • PITRAK DL: Filgrastim treatment of HIV-infected patients improves neutrophil function. AIDS (1999) 13\(Supp1.2):S25–S30.
  • WELCH W, FOOTE M: The use of filgrastim in AIDS-related neutropenia. Hematother. Stem. Cell Res. (1999) 8\(Supp1.1):59–516.
  • DAVIDSON M, MIN YI, HOLBROOK JT et al.: Influence of filgrastim (granulocyte colony-stimulating factor) on human immunodeficiency virus Type 1 RNA in patients with cytomegalovirus retinitis. Infect. Dis. (2002) 186:1013–1018.
  • KURITZKES DR: Clinical experience with filgrastim in AIDS. Hematother. Stem Cell Res. (1999) 8\(Supp1.1):S17–S19.
  • NIELSEN SD, SORENSEN TU, ALADDIN H et al.: The effect of long-term treatment with granulocyte colony-stimulating factor on hematopoiesis in HIV-infected individuals. Scand. I Immunol. (2000) 52:298–303.
  • DUBREUIL-LEMAIRE ML, GORI A, VITTECOQ D et al.: Lenograstim for the treatment of neutropenia in patients receiving ganciclovir for cytomegalovirus infection: a randomised, placebo-controlled trial in AIDS patients. Ear: I Haematol. (2000) 65:337–343.
  • ARMSTRONG WS, KAZANJIAN P: Use of cytokines in human immunodeficiency virus-infected patients: colony-stimulating factors, erythropoietin, and interleukin-2. Clin. Infect. Dis. (2001) 32:766–773.
  • IMAMI N, HARDY G, GOTCH F: Development of immunotherapeutic strategies for HIV-1. Expert. Opin. Biol. Ther (2001) 1:803–816.
  • PAU AK, TAVEL JA: Therapeutic use of interleukin-2 in HIV-infected patients. Curl: Opin. Pharmacol. (2001) 1:803–816.
  • TAMBUSSI G, GHEZZI S, NOZZA S et al.: Efficacy of low-dose intermittent subcutaneous interleukin (IL)-2 in antiviral drug-experienced human immunodeficiency virus-infected persons with detectable virus load: a controlled study of 3 IL-2 regimens with antiviral drug therapy. I Infect. Dis. (2001) 183:1476–1484.
  • MILLER KD, SPOONER K, HERPIN BR et al.: Immunotherapy of HIV-infected patients with intermittent interleukin-2: effects of cycle frequency and cycle duration on degree of CD4+ T lymphocyte expansion. Clin. Innnunol (2001) 99:30–42.
  • IMAMI N, HARDY G, BURTON C et al.: Immune responses and reconstitution in HIV-1 infected individuals: impact of anti-retroviral therapy, cytokines and therapeutic vaccination. Iminunol. Lett. (2001) 79:63–76.
  • SCHAEFER M, ENGELBRECHTA MA, GUT O et al.: Interferon a (IFN[a]) and psychiatric syndromes: a review. Prog. Neuropsychophannacol Biol. Psychiatry (2002) 26:731–746.
  • KOLIOUSKAS D, SIDIROPOULOS I, MASMANIDOU M, DOKAS S, ZIAKAS A: Comparative analysis of Peg-interferon a-2b and lamivudine in the treatment of chronic hepatitis B patients: preliminary results. Hepatol (2002) 36:237–238.
  • SANTANTONIO T, ANNA N, SINISI E et al.: Lamivudine/interferon combination therapy in anti-HBe positive chronic hepatitis B patients: a controlled pilot study. Hepatol (2002) 36:799–804.
  • SHAD JA, MCHUTCHISON JG: Currentand future therapies of hepatitis C. Clin. Liver Dis. (2001) 5:335–359.
  • PIMSTONE NR, CANTO JB, CHIANG MH: Ribavirin/interferon-2b therapy is very effective in the treatment of chronic hepatitis C genotype 2 and 3 patients who have failed to respond virologically to IFN monotherapy. (2001) 120:A–382.
  • LUXON BA, GRACE M, BRASSARD D, BORDENS R: Pegylated interferons for the treatment of chronic hepatitis C infection. Clin. The]: (2002) 24:1363–1383.
  • RAJENDER R, MODI MW, PEDDER S: Use of peginterferon a-2a (40 kDa) (Pegasys(A) for the treatment of hepatitis C. Adv. Drug Delivery Rev. (2002) 54:571–586.
  • BILLICH A: Thymosin al. SciClone Pharmaceuticals. Carr. Opin. Investig. Drugs (2002) 3:698–707.
  • SUGAHARA S, ICHIDA T, YAMAGIWA S et al.: Thymosin-[a]l increases intrahepatic NKT cells and CTLs in patients with chronic hepatitis B. Hepatol Res. (2002) 24:346–354.
  • ROTHENFUSSER S, TUMA E, ENDRES S, HARTMANN G: Plasmacytoid dendritic cells: the key to CpG. Hum. Innnunol. (2002) 24:346–354.
  • AKIRA S, HEMMI H: Recognition of pathogen-associated molecular patterns by TLR family. Irninunol. Lett. (2002) 24:346–354.
  • SAUDER DN: Immunomodulatory and pharmacologic properties of imiquimod. J. Ain. Acad. Dennatol (2000) 43:S6–S11.
  • STANLEY MA: Imiquimod and the imidazoquinolones: mechanism of action and therapeutic potential. Clin. Exp. Dennatol (2002) 27:571–577.
  • SYED TA, AHMADPOUR OA, AHMAD SA, AHMAD SH: Management of female genital warts with an analog of imiquimod 2% in cream: a randomized, double-blind, placebo-controlled study. .1. Dennatol (1998) 25:429–433.
  • TROFATTER KFJ: Imiqimod in clinical practice. Eui: Dennatol (1998) 8:17–19.
  • GILSON RJ, SHUPACK JL, FRIEDMAN-KIEN AE et al.: A randomized, controlled, safety study using imiquimod for the topical treatment of anogenital warts in HIV-infected patients. Imiquimod Study Group. AIDS(1999) 13:2397–2404.
  • HENGGE UR, BENNINGHOFF B, RUZICKA T, GOOS M: Topical immunomodulators-progress towards treating inflammation, infection, and cancer. The Lancet Infect. Dis. (2001) 1:189–198.

Website

  • http://www.who.int/csr/sars/en World Health Organisation (WHO). Severe acute respiratory syndrome (SARS). Internet Communication. (2003)

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.